12:00 AM
Feb 28, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

TMC435: Phase III started

Medivir said Johnson & Johnson's Tibotec Pharmaceuticals Ltd. unit began the double-blind, placebo-controlled, international Phase III QUEST-2 trial in 375 treatment-naïve patients with HCV genotype 1 to evaluate 150 mg oral TMC435 daily for 12...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >